biostudies-literatureUnknown10Tang Z<h4>Background</h4>This study examined the association between type 2 diabetes mellitus (T2DM) and 5-year overall survival (OS) in patients with pancreatic cancer (PC).<h4>Methods</h4>This retrospective cohort study included patients diagnosed with stage I/II PC at Shengjing Hospital of China Medical University from January 2012 to December 2017. All patients had pancreatic ductal adenocarcinoma or its subtypes. The outcome was the 5-year OS rate based on data from the patient charts. Data analysis was performed using SPSS 22.0.<h4>Results</h4>A total of 238 patients were included: 72 with T2DM and 166 without T2DM. There were significant differences in blood glucose levels and OS between the two groups (all <i>P</i> < 0.05). The median OS was 11.4 (95% confidence interval CI [8.49-14.31]) months in the T2DM group and 16.3 (95% CI [12.44-20.16], <i>P</i> = 0.023) months in the non-T2DM group. After adjustment for confounders, T2DM was an independent factor affecting 5-year OS (<i>P</i> = 0.010). Compared with non-T2DM patients, T2DM patients had a higher risk of death (HR = 1.475, 95% CI [1.096-1.985]).<h4>Conclusions</h4>T2DM is associated with 5-year OS in patients with PC.PeerJe14538https://www.ebi.ac.uk/biostudies/studies/S-EPMC9753753biostudies-literatureAssociation between type 2 diabetes and 5-year overall survival in early-stage pancreatic cancer: a retrospective cohort study.PMC9753753Tang ZZhang MXu WfalseAssociation between type 2 diabetes and 5-year overall survival in early-stage pancreatic cancer: a retrospective cohort study.<h4>Background</h4>This study examined the association between type 2 diabetes mellitus (T2DM) and 5-year overall survival (OS) in patients with pancreatic cancer (PC).<h4>Methods</h4>This retrospective cohort study included patients diagnosed with stage I/II PC at Shengjing Hospital of China Medical University from January 2012 to December 2017. All patients had pancreatic ductal adenocarcinoma or its subtypes. The outcome was the 5-year OS rate based on data from the patient charts. Data analysis was performed using SPSS 22.0.<h4>Results</h4>A total of 238 patients were included: 72 with T2DM and 166 without T2DM. There were significant differences in blood glucose levels and OS between the two groups (all <i>P</i> < 0.05). The median OS was 11.4 (95% confidence interval CI [8.49-14.31]) months in the T2DM group and 16.3 (95% CI [12.44-20.16], <i>P</i> = 0.023) months in the non-T2DM group. After adjustment for confounders, T2DM was an independent factor affecting 5-year OS (<i>P</i> = 0.010). Compared with non-T2DM patients, T2DM patients had a higher risk of death (HR = 1.475, 95% CI [1.096-1.985]).<h4>Conclusions</h4>T2DM is associated with 5-year OS in patients with PC.2022-01-01T00:00:00Z20222025-04-05T10:34:19.497Z2025-04-05T10:34:19.497ZS-EPMC97537533653040110.7717/peerj.14538